ATE524163T1 - Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren - Google Patents

Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren

Info

Publication number
ATE524163T1
ATE524163T1 AT01926775T AT01926775T ATE524163T1 AT E524163 T1 ATE524163 T1 AT E524163T1 AT 01926775 T AT01926775 T AT 01926775T AT 01926775 T AT01926775 T AT 01926775T AT E524163 T1 ATE524163 T1 AT E524163T1
Authority
AT
Austria
Prior art keywords
substituted
pharmaceutical composition
dihydroxyheptenoic
pharmaceutical compositions
acids
Prior art date
Application number
AT01926775T
Other languages
English (en)
Inventor
Michael Fox
Ivo Dorossiev
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22723348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE524163(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE524163T1 publication Critical patent/ATE524163T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
AT01926775T 2000-04-10 2001-04-09 Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren ATE524163T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19591600P 2000-04-10 2000-04-10
PCT/US2001/011514 WO2001076566A1 (en) 2000-04-10 2001-04-09 Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids

Publications (1)

Publication Number Publication Date
ATE524163T1 true ATE524163T1 (de) 2011-09-15

Family

ID=22723348

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926775T ATE524163T1 (de) 2000-04-10 2001-04-09 Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren

Country Status (12)

Country Link
US (2) US6558659B2 (de)
EP (2) EP1274401B2 (de)
AT (1) ATE524163T1 (de)
AU (2) AU2001253287B2 (de)
CA (1) CA2406574C (de)
CY (1) CY1112963T1 (de)
DK (2) DK1274401T4 (de)
ES (2) ES2372682T5 (de)
IL (1) IL152179A (de)
PT (2) PT1274401E (de)
WO (1) WO2001076566A1 (de)
ZA (1) ZA200208168B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
WO2003000177A2 (en) * 2001-06-21 2003-01-03 Andrx Pharmaceuticals, Inc. Stable controlled release pharmaceutical compositions containing pravastatin
KR100514590B1 (ko) * 2001-12-18 2005-09-14 주식회사 대웅 프라바스타틴나트륨 및 안정화제로서의 코폴리비돈을함유하는 약제 조성물
US20030162827A1 (en) * 2002-01-30 2003-08-28 Suresh Venkataram HMG CoA reductase inhibiting composition, method of preparation thereof and method for competitively inhibiting HMG CoA reductase using such composition
HUP0201083A2 (hu) * 2002-03-28 2004-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények
CA2379887C (en) * 2002-04-09 2004-01-20 Bernard Charles Sherman Stable tablets comprising simvastatin
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
SI21400A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska družba d.d. Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
US7642287B2 (en) * 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
WO2006017692A2 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
KR20080079646A (ko) * 2005-11-21 2008-09-01 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 제제
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
US7772273B2 (en) * 2006-02-10 2010-08-10 Lifecycle Pharma A/S Stabilized atorvastatin
KR20080094837A (ko) * 2006-02-24 2008-10-24 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 약학 조성물
US20080038332A1 (en) * 2006-08-10 2008-02-14 Cai Gu Huang Stable pharmaceutical formulation comprising atorvastatin calcium
EP1911441A3 (de) * 2006-10-11 2008-08-06 Lupin Limited Farbstabile pharmazeutische Dosierungsformen mit kontrollierter Freigabe von HMG-COA-Reduktase-Hemmern, die frei von Alkalisierungs- oder Pufferagenzien sind
WO2008064259A2 (en) * 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
EP2134169A2 (de) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Kombination von metformid-r-(+)-lipoat und antihyperlipidämika für die behandlung von diabetes-hyperglykämie und diabetesbedingte komplikationen
GB0713707D0 (en) * 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
IN2014CN04119A (de) 2011-11-15 2015-07-10 Reddys Lab Ltd Dr
CN105030698A (zh) * 2015-09-16 2015-11-11 青岛华之草医药科技有限公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物颗粒剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5078997A (en) † 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
GB8903593D0 (en) † 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
GB2231813A (en) 1989-05-17 1990-11-28 Ford Motor Co Emission control
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
CA2150372C (en) * 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5627200A (en) * 1994-09-26 1997-05-06 Pfizer Inc β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
DE19725391A1 (de) 1997-06-16 1998-12-17 Bayer Ag Verfahren zur Herstellung von Arzneimittel, enthaltend HMG-CoA-Reduktase-Inhibitoren
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6207664B1 (en) 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
KR20010080722A (ko) 1998-12-09 2001-08-22 추후제출 배형체를 사용한 독성 타이핑
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
CA2365869A1 (en) 1999-03-08 2000-09-14 Richard D. Tillyer Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
US6465011B2 (en) † 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
GB0001621D0 (en) † 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij

Also Published As

Publication number Publication date
US20020035142A1 (en) 2002-03-21
DK1274401T3 (da) 2011-12-12
AU5328701A (en) 2001-10-23
EP1274401B2 (de) 2014-08-13
USRE39502E1 (en) 2007-03-06
EP2382970B1 (de) 2013-01-09
US6558659B2 (en) 2003-05-06
EP1274401A4 (de) 2009-07-22
ES2401598T3 (es) 2013-04-22
DK2382970T3 (da) 2013-03-25
WO2001076566A1 (en) 2001-10-18
CA2406574A1 (en) 2001-10-18
IL152179A0 (en) 2003-05-29
DK1274401T4 (da) 2014-09-08
EP1274401B1 (de) 2011-09-14
EP2382970A1 (de) 2011-11-02
AU2001253287B2 (en) 2005-04-28
CA2406574C (en) 2006-12-05
PT2382970E (pt) 2013-02-18
IL152179A (en) 2009-06-15
ZA200208168B (en) 2003-10-10
CY1112963T1 (el) 2016-04-13
PT1274401E (pt) 2011-12-02
ES2372682T5 (es) 2014-10-30
EP1274401A1 (de) 2003-01-15
ES2372682T3 (es) 2012-01-25

Similar Documents

Publication Publication Date Title
ATE524163T1 (de) Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren
BRPI0714055B8 (pt) compostos moduladores de propriedades farmacocinéticas de terapêuticos, composições farmacêuticas que compreendem os referidos compostos e usos dos mesmo
IL174665A0 (en) Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
DK1318788T3 (da) Nanopartikulær fastdosissammensætninger
CO5640071A2 (es) Composiciones farmaceuticas de atorvastatina
DK1901736T3 (da) Farmaceutisk sammensætning omfattende simvastatin og ezetimib
UA41346C2 (uk) Фармацевтична композиція, яка містить флуоксетин або його сіль, таблетка на її основі, спосіб виробництва таблетки, яка диспергується
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
HK1084582A1 (en) Stable solid medicinal composition for oral administration
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
SE9901573D0 (sv) New compounds
HK1108633A1 (en) Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
MX9400800A (es) Un complejo de estabilizacion neutro para ci-979 hci, un activador de la cognicion.
EA201100430A1 (ru) Стабильная комбинированная фармацевтическая композиция
WO2007064620A3 (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
BR9812385A (pt) Formulações parasiticidas
ES2298262T3 (es) Estabilizacion de formulaciones de farmacos tiroideos solidas.
HK1055675A1 (en) Method for stabilizing a pharmaceutical preparation
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
PT97164A (pt) Processo para a estabilizacao de uma preparacao que contenham o composto 4-etil-2-hidroxi-imino-5-nitro-3-hexenamida e de composicoes farmaceuticas que o contenham
CY1114106T1 (el) Σταθερες φαρμακευτικες συνθεσεις που περιεχουν 7-υποκατεστημενα-3,5-διυδροξυεπτανοϊκα οξεα ή 7-υποκατεστημενα-3,5-διυδροξυεπτενοϊκα οξεα
HUP0200337A2 (hu) Stabilizált provastatin-nátriumot tartalmazó gyógyászati készítmény
MX2023003401A (es) Composicion farmaceutica para prevenir o tratar enfermedad hepatica colestasica, que contiene beta-lapachona como ingrediente activo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1274401

Country of ref document: EP